WASHINGTON (Reuters) - Drug makers could face fines if they fail to complete post-approval studies or otherwise violate safety monitoring plans for recently approved medicines under legislation proposed by two key senators.
WASHINGTON (Reuters) - Drug makers could face fines if they fail to complete post-approval studies or otherwise violate safety monitoring plans for recently approved medicines under legislation proposed by two key senators.
